Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus

被引：7
|
作者：
Nepal, Desh [1 ,2 ]
Gazeley, David [1 ]
机构：
[1] Med Coll Wisconsin, Dept Med, Div Rheumatol, Milwaukee, WI USA
[2] Med Coll Wisconsin, Rheumatol, Hub Collaborat Med, 8701 Watertown Plan Rd,6th Floor, Milwaukee, WI 53226 USA
来源：
RHEUMATOLOGY | 2023年 / 62卷 / 12期
关键词：
IL-6; inhibition; SLE; tocilizumab; sirukumab; OF-RHEUMATOLOGY GUIDELINE; PHASE PROTEIN RESPONSE; MONOCLONAL-ANTIBODY; DISEASE-ACTIVITY; MURINE LUPUS; T-CELLS; INTERLEUKIN-6; TOCILIZUMAB; EFFICACY; RECEPTOR;
D O I：
10.1093/rheumatology/kead416
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Interleukin-6 is one of the cytokines implicated in murine and human SLE. Only a few small studies have investigated IL-6 inhibition in human SLE. Currently, there are no studies registered in clinicaltrials.gov to assess the IL-6 targeted therapy in SLE, yet its role in the future remains to be defined. This narrative review analyses these and potential areas of future studies with IL-6 targeted therapy in SLE. A video abstract is available for this article and can be viewed at https://doi.org/10.1093/rheumatology/kead416.
引用
收藏
页码：3804 / 3810
页数：7
相关论文
共 50 条
  • [21] The role of intratumoral and systemic IL-6 in breast cancer
    Christine Dethlefsen
    Grith Højfeldt
    Pernille Hojman
    Breast Cancer Research and Treatment, 2013, 138 : 657 - 664
  • [22] The role of intratumoral and systemic IL-6 in breast cancer
    Dethlefsen, Christine
    Hojfeldt, Grith
    Hojman, Pernille
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (03) : 657 - 664
  • [23] Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL-Faslpr Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus
    Cash, Hannes
    Relle, Manfred
    Menke, Julia
    Brochhausen, Christoph
    Jones, Simon A.
    Topley, Nicholas
    Galle, Peter R.
    Schwarting, Andreas
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (01) : 60 - 70
  • [24] The Expression of Molecular Chaperone HSP90 and IL-6 in Patients with Systemic Lupus Erythematosus
    胡绍先
    徐卿
    萧文泽
    Huang Melissa
    华中科技大学学报(医学英德文版), 2006, (06) : 664 - 666
  • [25] The expression of molecular chaperone HSP90 and IL-6 in patients with systemic lupus erythematosus
    Hu S.
    Xu Q.
    Xiao W.
    Huang M.
    Journal of Huazhong University of Science and Technology, 2006, 26 (6): : 664 - 666
  • [26] Systemic IL-6 and Severe Asthma
    Lipworth, Brian
    Chan, Rory
    Kuo, Chris
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 202 (09) : 1324 - 1325
  • [27] IL-6/IL-6 receptor system and its role in physiological and pathological conditions
    Mihara, Masahiko
    Hashizume, Misato
    Yoshida, Hiroto
    Suzuki, Miho
    Shiina, Masashi
    CLINICAL SCIENCE, 2012, 122 (3-4) : 143 - 159
  • [28] The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor?
    Pedersen, BK
    Steensberg, A
    Fischer, C
    Keller, C
    Keller, P
    Plomgaard, P
    Wolsk-Petersen, E
    Febbraio, M
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2004, 63 (02) : 263 - 267
  • [29] Interleukin-6 (IL-6) production by astrocytes: Autocrine regulation by IL-6 and the soluble IL-6 receptor
    Van Wagoner, NJ
    Oh, JW
    Repovic, P
    Benveniste, EN
    JOURNAL OF NEUROSCIENCE, 1999, 19 (13): : 5236 - 5244
  • [30] IL-6, IL-10 and IL-4 expression and cross-talk in patients with systemic lupus erythematosus (SLE).
    Honda, M
    Nand, R
    Mandyam, R
    Mengesha, E
    Wallace, DJ
    Metzger, A
    Bharier, B
    Klineberg, JR
    Morris, R
    Linker-Israeli, M
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S39 - S39
12345